Pembrolizumab plus chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- You have not received any previous treatment for this cancer.
- Your cancer is HER2-negative (a specific protein test).
- You are in generally good health (able to do daily activities, with good blood counts and kidney/liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as a first treatment for people with advanced or metastatic stomach or gastroesophageal junction cancer. It's looking for patients whose tumors have a specific protein called CLDN18.2, and who have not had prior treatment for advanced disease.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This trial tests a new immunotherapy drug called rilvegostomig combined with standard chemotherapy to see if it can help people with advanced stomach or gastroesophageal junction cancer. It may boost the body's immune system to fight the cancer better.
Hear when a new Gastroesophageal-junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.